New Model to Detect and Combat Lung Cancer Recurrence

A new process to study vulnerabilities of circulating tumor cells responsible for cancer recurrence in lung cancer patients discovered.

A new process to study the movements and vulnerabilities of circulating tumor cells responsible for cancer recurrence in patients with non-small cell lung cancer (NSCLC) has been discovered by researchers.

Non-small cell lung cancer (NSCLC) is a devastating disease and the leading cause of American cancer deaths. Even patients suitable for tumor removal have a 50% mortality rate.

Lung Cancer - Types, Causes, Symptoms, Diagnosis, Treatment and Prevention
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with symptoms like recurrent respiratory diseases.

‘Injecting human tumor cells into mice provides new way to study and prevent lung cancer.’

The researchers took tumor fragments from ten human NSCLC patients and injected them into immunodeficient mice. Circulating tumor cells from those mice were identified, isolated and then injected as liquid biopsies into another group of mice to create study models. Researchers watched as two of the ten patient samples of circulating tumor cells became stable tumors in the mouse models.

“These circulating tumor cells have enhanced metastatic potential, and our models showed that these cell clusters correlated with cancer recurrence,” said study author Jussuf Kaifi, MD, a cancer surgeon at MU Health Care and an assistant professor of surgery at the MU School of Medicine. “These findings show our liquid biopsy model can be a valuable tool to study and predict the risk of future recurrences and metastases after curative removal of localized lung cancer in individual patients.”

Kaifi’s team also tested the resistance of these tumor cells to chemotherapy and found a protein coding gene called MYC may be responsible for tumor resistance to a common chemotherapy. By blocking MYC in the mouse models, researchers found the tumor cells to be much more vulnerable to chemotherapy treatment.

Lung Cancer Screening - FAQs
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.

“This mouse model generated from the tumors of lung cancer patients offers valuable drug sensitivity testing platforms, possibly in a time window before patients develop incurable recurrence,” Kaifi said.

One other notable finding, researchers discovered the tumors that developed in the mouse model differed from the primary tumors extracted from the human patients. The mouse models had a second set of a specific protein believed to play a role in metastasis development that matched the profile of humans with metastatic lung cancer.

Quiz on Lung Cancer (Advance)
Lung cancer, like other cancers, is a dreaded condition responsible for a number of deaths in both men and women. Test your knowledge on lung cancer by taking this quiz.

“The finding of a second protein cell population in both the mouse model and patient metastases represents an exciting avenue for future research on circulating tumor cells and metastasis development,” Kaifi said.

In addition to Kaifi, the study authors include MU postdoctoral fellows Kanve Suvilesh, PhD, Yariswamy Manjunath, PhD, and Vijay Radhakrishnan, PhD; Jonathan Mitchem, MD, assistant professor of surgery; Eric Kimchi, MD, the John A. Growden Distinguished Professorship in Surgery; Kevin Staveley-O’Carroll, MD, professor of surgery; Chi-Ren Shyu, PhD, director, MO Informatics Institute; Guangfu Li, PhD, assistant professor of surgery; and Wesley Warren, PhD, professor of genomics.

Blood Test Helps Predict Who may Benefit from Lung Cancer Screening
A new blood test combined with a risk model based on the person's history accurately helps determine who is likely to benefit from lung cancer screening.

Their study, “Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses” was recently published by the journal Molecular Cancer. Research reported in this publication was supported by a Mizzou Advantage Interdisciplinary Research Grant and funding from the Department of Veterans Affairs. The authors of the study declare that they have no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Source-Eurekalert